Tilray Medical has relaunched its cannabis oral solution in Ireland, which patients will be able to get reimbursed under the Irish Medical Cannabis Access Scheme.
Tilray Brands has successfully relaunched the solution which is produced under European GMP under the National Medical Cannabis Access Program (MCAP).
The product has received reimbursement registration, enabling patients to reimburse costs and ensuring that those most eligible have access to quality medical cannabis under the Irish MCAP.
Read more: Tilray Medical granted market authorisation in Poland
Denise Faltischek, Chief Strategy Officer and Head of International Affairs, Tilray Brands, stated: “We are extremely proud to re-launch this product in Ireland with an expanded footprint.
“Approval for reimbursement under MCAP is an extraordinary step in providing patients with greater access to Tilray’s high-quality medical cannabis products that meet their needs.
“We remain dedicated to doing our part to improve access for patients in need of these products worldwide.”
The company has stated that it intends to supply its full range of medical cannabis products to Irish patients once local regulations permit.
Earlier in September, Tilray confirmed that FL Group S.R.L., a division of Tilray Medical in Italy, received approval to import and distribute Tilray’s medical cannabis oral solution across the country.
Approval was received from the Italian Ministry of Health. Medical cannabis authorisation is currently limited in the country, and Tilray Medical has an established national pharmaceutical distribution network with FL Group to distribute the solution.
Italian patients may obtain prescriptions for Tilray and other medical cannabis products in Italy through their medical doctor.
[activecampaign form=31]
